Wall Street opened the week in positive territory, lifted by expectations of a Fed rate cut next week — potentially a 50 bp one — and growing speculation of a more dovish policy path ahead. The Nasdaq (US100: +0.7%) and S&P 500 (US500: +0.25%) are advancing, while the Dow Jones (US30: -0.05%) lags, reflecting caution ahead of the key U.S. CPI release.
Volatility of US-listed stocks. Techs prevail as the strongest performers today, while Healthcare, Pharma, Financials and Industrials are seeing a mixed-to-negative sentiment. Source: xStation
US500 (D1)
S&P 500 futures are rebounding 0.25% after testing the 10-day exponential moving average (EMA10; yellow), with price action gradually tightening within its ascending channel. The index has yet to fully recover from the post-NFP selloff, though sentiment remains supported by a broader global equity rally ahead of key political events, including the French PM’s confidence vote, and the upcoming U.S. CPI release on Thursday. The RSI is nearing overbought territory, but history suggests the U.S. equity rally is unlikely to reverse without a materially negative macroeconomic signal that points to a slowdown capable of significantly pressuring corporate earnings. From a technical point of view, the uptrend should be safe as long as the price holds above the key support of 6450.
Source: xStation5
Company news:
-
AppLovin (APP.US), Robinhood Markets (HOOD.US) and Emcor Group Inc. (EME.US) are all posting gains after S&P Dow Jones Indices said the stocks would be added to the S&P 500 Index.
-
Dianthus Therapeutics (DNTH.US) adds 3% after its Phase 2 trial showed claseprubart delivered rapid, statistically significant improvements in generalized Myasthenia Gravis patients, with efficacy seen as early as Week 1. Both 300mg and 600mg doses performed well, with favorable safety, supporting plans for a Phase 3 trial starting in 2026
-
EchoStar shares soar 17% after the announcement that SpaceX will buy company’s AWS-4 and H-block spectrum licenses for about $17 billion, paying up to $8.5 billion in cash, the same in stock, and covering $2 billion in EchoStar debt interest through 2027. The deal resolves FCC probes, helps EchoStar cut its $25B debt, and strengthens SpaceX’s push into direct-to-device mobile services, complementing its Starlink network.
-
Ideaya Biosciences (IDYA.US) drops 4% despite the report that early Phase 1 data showed its lung cancer drug IDE849, co-developed with Hengrui Pharma, delivered a 74% overall response rate and 58% confirmed rate across treatment settings, with 6.7 months median PFS. RBC said results suggest “best-in-class potential.”
-
Qualcomm and Google Cloud are teaming up to bring multimodal AI agents to vehicles, combining Google’s Gemini-powered Automotive AI Agent with Qualcomm’s Snapdragon Digital Chassis. The partnership blends on-device and cloud inference for faster, more personalized experiences, offering automakers a toolkit and reference architecture to accelerate development of software-defined cars.
WTI Crude Plunges Over 2% to Lowest Level Since May
AMD Gains 3% on Oracle Processor Integration Announcement
Coffee Futures Soar 5%, Break 400 Cents per Pound
US100 loses 1% 📉
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
